PMC

Plaque stabilisation in acute coronary syndromes. ACE angiotensin converting enzyme; ACS, acute coronary syndrome; AMI, acute mycocardial infarction; GP, glycoprotein; LMWH, low molecular weight heparin; PCI, percutaneous coronary intervention.

Schematic representation of (a) magnetic particles, (b) activated with functional groups, and (c) conjugated to biological molecules []; (d) solution stability of antibody-modified magnetic particles over 3 months at 32°C using stabilisers from Applied Enzyme Technology Ltd. Activity tested by optical magneto-immunoassay using 15 ng/ml PSA, 0.1 mg/ml anti-PSA antibody-modified magnetic particles (Abcam, ab10184) and 1 μg/ml horseradish peroxidase (HRP)-labelled antibody (Abcam, ab24466).

Temperature stability. a Incubation of KdgDAb1 (100 % = 6.22 U/mg), KdgDAb2 (100 % = 6.56 U/mg), KdgDCt (100 % = 5.5 U/mg) and KdgDPn (100 % = 3.7 U/mg) at 37 °C; b Incubation of KdgDAb1 (100 % = 8.22 U/mg), KdgDAb2 (100 % = 8.1 U/mg), KdgDCt (100 % = 8.4 U/mg) and KdgDPn (100 % = 5.1 U/mg) at 65 °C; assay: volume 200 μl, 2.5 mM KP_i (pH 7.0), 2 mM MgCl₂, 25 μg/ml BTB and 5 mM 5-keto-4-D-deoxyglucarate; enzyme was incubated in 100 μl of 5 mM KP_i (pH 7.0); only KdgDAb1 differed, where additional 0.5 mM NH₄HCO₃ was used for enzyme stabilisation

Change in T _m of hexokinase in the presence of different sugars. The trend line was fitted to the modified Michaelis–Menten kinetics given in Eqn . The stabilisation effect could be used to estimate affinity of substrates or potential inhibitors (K _M or K _i). Symbols represent d‐mannose, d‐glucose, 2‐deoxy‐d‐glucose, N‐acetyl‐d‐glucosamine and d‐xylose.